A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
Status:
TERMINATED
Trial end date:
2025-01-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies.
Participants will be given imvotamab through a vein (i.e., intravenously).